Last updated on December 2019

Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ornithine carbamoyltransferase deficiency
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Males and females 18 years of age with documented diagnosis of late onset (defined as first manifestation of signs and symptoms at 1 month of age) OTC deficiency, confirmed via enzymatic, biochemical, or molecular testing
  2. Documented history of 1 symptomatic hyperammonemia event with ammonia 100 mol/L.
  3. Subject's OTC deficiency is stable as evidenced by either a) no clinical symptoms of hyperammonemia OR b) an ammonia level <100 mol/L within the 4 week period preceding the Screening visit.
  4. On stable dose of ammonia scavenger therapy for 4 weeks.
  5. Males and all females of childbearing potential must be willing to use effective contraception at the time of administration of gene transfer and for the 52 weeks following administration of DTX301

Exclusion Criteria:

  1. Screening or Baseline (Day 0) ammonia level 100 mol/L or signs and symptoms indicative of hyperammonemia during the 4-week period preceding Day 0
  2. Liver transplant, including hepatocyte cell therapy/transplant.
  3. History of liver disease
  4. Serum creatinine >2.0 mg/dL.
  5. Participation in another investigational medicine study (including another gene transfer trial) within 3 months of Screening
  6. History of a malignancy for which the subject has received treatment in the past 2 years except for prostate cancer treated with watchful waiting or surgically removed non-melanoma skin cancer.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.